According to a new market research report from MarketsandMarkets, the infectious disease diagnostics market could be worth $39.8 billion by 2026. Growing awareness for early disease diagnosis, the prevalence of infectious diseases worldwide and onset of COVID-19 are factors supporting the high growth of this particular market.

The infectious disease market is segmented into reagents, kits and consumables, instruments, software and services. The reagents, kits, and consumables segment accounted for the largest share of the market, by product & service segment, in 2020. The point-of-care testing segment is to register the highest CAGR (Compound Annual Growth Rate) during the forecast period.

In 2020, the COVID-19 disease type segment accounted for the largest share of this market. MarketsandMarkets provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues.

North America is the largest regional market for infectious disease diagnostics. Based on disease type, the market is segmented into COVID-19, HIV, HAIs, hepatitis, CT/NG, HPV, TB, influenza, and other infectious diseases. Diagnostic laboratories command the major share of the market owing to increased test volume of infectious diseases and strengthening healthcare infrastructure for efficient disease diagnosis and treatment.

The global forecast PDF file from MarketsandMarkets can be found here.